Beam Therapeutics

BEAM Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$24.66

+1.82% today

52W: $13.53 – $36.44

52W Low: $13.53 Position: 48.6% 52W High: $36.44

🔗 Compare Brokers Best Broker for Beginners →

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

17.97x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.5B

Market Capitalization

Revenue Growth

279.5%

YoY Revenue Growth

Profit Margin

-57.24%

Net profit margin

ROE

-8.11%

Return on Equity

Beta

2.19

Market sensitivity

Short Interest

23.48%

% of float sold short

Avg. Volume

2,018,347

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

15 analysts

Avg. Price Target

$51.20

+107.62% upside

Target Range

$26.00 – $80.00

About the Company

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, i

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 511 Exchange: NMS